SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the first patient has enrolled ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the use of ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (UTHR) announced today that it will host a webcast to review data from the successful TETON-2 ...

United Therapeutics shares reached a new 52-week high after the firm reported that the U.S. FDA granted approval to commercially launch its Tyvaso® Inhalation Solution to treat patients with pulmonary ...

Treprostinil 16mcg, 32mcg, 48mcg, 64mcg; per cartridge; dry pwd for inh. Ampules (2.9mL)—4; Starter Kit—1 (28 ampules with inhalation system); Refill Kit—1 (28 ampules with accessories); DPI Titration ...

United Therapeutics Corporation UTHR announced that the FDA has approved the new drug application for the dry powder inhalation (DPI) formulation for its key pulmonary arterial hypertension (PAH) drug ...

CBS News pulled a "60 Minutes" report on El Salvador's CECOT prison just hours before its scheduled Sunday broadcast, saying it would air at a future time. Reuters, the news and media division of ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five presentations and one poster ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food and Drug ...

United Therapeutics UTHR reported fourth-quarter 2025 earnings per share (EPS) of $7.70, which surpassed the Zacks Consensus Estimate of $6.78. Earnings increased 24% year over year, driven by higher ...

Second registration study of Tyvaso® (treprostinil) Inhalation Solution for patients with IPF Subjects will be randomly allocated 1:1 to receive Tyvaso or placebo. All subjects will initiate Tyvaso or ...